The acquired Brugada syndrome and the paradox of choice

Heart Rhythm

Volumn 6, Issue 9, 2009, Pages 1342-1344

  Viskin, Sami ^a   Rosso, Raphael ^b   Márquez, Manlio F ^c   Antzelevitch, Charles ^d  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^d MASONIC MEDICAL RESEARCH LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE; POTASSIUM CHANNEL; PROCAINAMIDE; QUINIDINE; SODIUM CHANNEL; SODIUM CHANNEL BLOCKING AGENT; ANESTHETIC AGENT; ANTIARRHYTHMIC AGENT; PSYCHOTROPIC AGENT;

BRUGADA SYNDROME; CARDIAC PATIENT; CARDIOVASCULAR RISK; CHANNELOPATHY; CLINICAL EVALUATION; DEFIBRILLATOR; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; DRUG INFORMATION; DRUG SAFETY; DRUG SCREENING; EDITORIAL; GENE MUTATION; GENETIC VARIABILITY; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INTERNET; LOSS OF FUNCTION MUTATION; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; ST SEGMENT ELEVATION; SYNCOPE; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; DIAGNOSTIC USE; PATIENT CARE;

ANESTHETICS; ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; INTERNET; PATIENT CARE; PSYCHOTROPIC DRUGS;

EID: 68949215038     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2009.07.033     Document Type: Editorial

References (34)

1. Antzelevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm 2 (2005) 429-440
2. Jervell A., and Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 54 (1957) 59-68
3. Romano C., Gemme G., and Pongiglione R. Aritmie cardiache rare dell'eta pediatrica. Clin Pediatr 45 (1963) 656-683
4. Ward O.C. A new familial cardiac syndrome in children. J Irish Med Assoc 54 (1964) 103-106
5. Selzer A., and Wray H.W. Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30 (1964) 17-26
6. Jackman W.M., Friday K.J., Anderson J.L., Aliot E.M., Clark M., and Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 31 (1988) 115-172
7. Kr potassium channel. Cell 81 (1995) 229-307
8. Sesti F., Abbott G.W., Wei J., et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci U S A 97 (2000) 10613-10618
9. Kaab S., Hinterseer M., Nabauer M., and Steinbeck G. Sotalol testing unmasks altered repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using i.v. sotalol. Eur Heart J 24 (2003) 649-657
10. Jeyaraj D., Abernethy D.P., Natarajan R.N., et al. I(Kr) channel blockade to unmask occult congenital long QT syndrome. Heart Rhythm 5 (2008) 2-7
11. Brugada P., and Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 20 (1992) 1391-1396
12. Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol 9 (1998) 513-516
13. Chen Q., Kirsch G.E., Zhang D., et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392 (1998) 293-296
14. Brugada R., Brugada J., Antzelevitch C., et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 101 (2000) 510-515
15. Wilde A.A., Antzelevitch C., Borggrefe M., et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 106 (2002) 2514-2519
16. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
17. Vincent G.M., Schwartz P.J., Denjoy I., et al. High efficacy of beta-blockers in long-QT syndrome type 1: contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment "failures.". Circulation 119 (2009) 215-221
18. Postema P.G., Wolpert C., Amin A.S., et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). Heart Rhythm 6 (2009) 1335-1341
19. Dole V.P., Nyswander M.E., and Kreek M.J. Narcotic blockade-a medical technique for stopping heroin use by addicts. Trans Assoc Am Physicians 79 (1966) 122-136
20. Krantz M.J., Lewkowiez L., Hays H., Woodroffe M.A., Robertson A.D., and Mehler P.S. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med 137 (2002) 501-504
21. Fenichel R.R., Malik M., Antzelevitch C., et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15 (2004) 475-495
22. Haverkamp W., Breithardt G., Camm A.J., et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 21 (2000) 1216-1231
23. Antzelevitch C. Arrhythmogenic mechanisms of QT prolonging drugs: is QT prolongation really the problem?. J Electrocardiol 37 Suppl (2004) 15-24
24. Towart R., Linders J.T., Hermans A.N., et al. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?. J Pharmacol Toxicol Methods (2009) (In press)
25. Extramiana F., and Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 110 (2004) 3661-3666
26. Patel C., and Antzelevitch C. Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm 5 (2008) 585-590
27. Fish J.M., and Antzelevitch C. Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm 1 (2004) 210-217
28. Calloe K., Cordeiro J.M., Di Diego J.M., et al. A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res 81 (2009) 686-694
29. Malik M. The imprecision in heart rate correction may lead to artificial observations of drug induced QT interval changes. Pacing Clin Electrophysiol 25 (2002) 209-216
30. Shimizu W., Matsuo K., Takagi M., et al. Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 11 (2000) 396-404
31. Nishizaki M., Sakurada H., Mizusawa Y., et al. Influence of meals on variations of ST segment elevation in patients with Brugada syndrome. J Cardiovasc Electrophysiol 19 (2008) 62-68
32. Shimeno K., Takagi M., Maeda K., Tatsumi H., Doi A., and Yoshiyama M. Usefulness of multichannel Holter ECG recording in the third intercostal space for detecting type 1 Brugada ECG: comparison with repeated 12-lead ECGs. J Cardiovasc Electrophysiol (2009) (In press)
33. Viskin S., Justo D., Halkin A., and Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 45 (2003) 415-427
34. Zeltser D., Justo D., Halkin A., Prokhorov V., Heller K., and Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 82 (2003) 282-290